Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
Edward A MoteaFarjana J FattahLing XiaoLuc GirardAmy RommelJulio C MoralesPraveen PatidarYunyun ZhouAndrew PorterYang XieJohn D MinnaDavid A BoothmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Cancer cells with low K-H expression may have exploitable BRCAness properties that greatly expand the use of PARP inhibitors beyond BRCA mutations. Our results suggest that aberrant K-H alterations may have vital translational implications in cellular responses/survival to DNA damage, carcinogenesis, and personalized medicine.